Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multinational, Double-blind, Placebo-controlled, Parallel-group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Glatiramer Acetate in Subjects With Multiple Sclerosis

NCT00475865 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00475865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00475865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multinational, Double-blind, Placebo-controlled, Parallel-group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Glatiramer Acetate in Subjects With Multiple Sclerosis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
October 31, 2009
Enrollment
123 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis